We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+12.07%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$1.23B
AUM Growth
+$191M
Cap. Flow
+$102M
Cap. Flow %
8.28%
Top 10 Hldgs %
30.7%
Holding
101
New
8
Increased
39
Reduced
39
Closed
6

Top Buys

Rank Stock Value
1
INSP icon
Inspire Medical Systems
INSP
+$18.2M
2
EXAS
Exact Sciences
EXAS
+$18.1M
3
MDT icon
Medtronic
MDT
+$13.5M
4
NVO
Novo Nordisk
NVO
+$13.3M
5
APLS
Apellis Pharmaceuticals
APLS
+$11.6M

Top Sells

Rank Stock Value
1
ELV icon
Elevance Health
ELV
+$18.9M
2
UNH icon
UnitedHealth
UNH
+$18.4M
3
CI icon
Cigna
CI
+$11.2M
4
OSCR icon
Oscar Health
OSCR
+$9.64M
5
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$9.15M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
2 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ABT icon
26
Abbott
ABT
$188B
$15.4M 1.25%
135,000
-10,000
-7% -$1.1M
ITCI
27
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$15M 1.22%
205,500
+63,500
+45% +$4.77M
MCK icon
28
McKesson
MCK
$103B
$14.9M 1.21%
30,117
+117
+0.4% +$65.2K
GKOS icon
29
Glaukos
GKOS
$10.7B
$14.5M 1.17%
111,000
+61,000
+122% +$7.59M
CI icon
30
Cigna
CI
$73.6B
$14.4M 1.17%
41,685
-32,486
-44% -$11.2M
ALGN icon
31
Align Technology
ALGN
$12.5B
$14M 1.14%
55,000
-1,500
-3% -$354K
ALNY icon
32
Alnylam Pharmaceuticals
ALNY
$29B
$13.8M 1.12%
50,350
-35,150
-41% -$9.15M
DVAX
33
DELISTED
Dynavax Technologies
DVAX
$13.3M 1.08%
1,190,000
-42,361
-3% -$467K
BIIB icon
34
Biogen
BIIB
$30.6B
$13M 1.06%
67,100
-17,700
-21% -$3.7M
NVO
35
Novo Nordisk
NVO
$211B
$11.9M 0.97%
+100,000
New +$13.3M
CVS icon
36
CVS Health
CVS
$122B
$11.6M 0.94%
+184,000
New +$10.7M
IQV icon
37
IQVIA
IQV
$39.8B
$11.4M 0.92%
48,000
+17,000
+55% +$4.01M
AXSM icon
38
Axsome Therapeutics
AXSM
$11.4B
$11M 0.89%
122,600
-5,000
-4% -$436K
APLS
39
DELISTED
Apellis Pharmaceuticals
APLS
$10.6M 0.86%
367,500
+312,105
+563% +$11.6M
JAZZ icon
40
Jazz Pharmaceuticals
JAZZ
$16.7B
$10.4M 0.84%
93,000
-21,000
-18% -$2.3M
MOH icon
41
Molina Healthcare
MOH
$10.4B
$10.2M 0.83%
29,600
+22,600
+323% +$7.46M
COR icon
42
Cencora
COR
$62B
$10.2M 0.82%
45,150
-6,350
-12% -$1.47M
IOVA icon
43
Iovance Biotherapeutics
IOVA
$2.9B
$9.88M 0.8%
1,052,500
+132,500
+14% +$1.26M
HUM icon
44
Humana
HUM
$46.3B
$9.82M 0.8%
+31,000
New +$11M
CYTK icon
45
Cytokinetics
CYTK
$10.5B
$9.53M 0.77%
180,500
-17,015
-9% -$948K
INSM icon
46
Insmed
INSM
$29.4B
$9.45M 0.77%
129,513
+30,000
+30% +$2.21M
PODD icon
47
Insulet
PODD
$9.91B
$9.31M 0.76%
40,000
-6,500
-14% -$1.33M
NUVL
48
DELISTED
Nuvalent
NUVL
$9.21M 0.75%
90,000
+7,250
+9% +$601K
CNC icon
49
Centene
CNC
$32.9B
$8.81M 0.71%
116,982
-81,500
-41% -$5.97M
SYK icon
50
Stryker
SYK
$133B
$8.31M 0.67%
23,000
+5,000
+28% +$1.73M
1
2
3 4 5

Similar funds

ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return
AF
Ally Financial Detroit, Michigan $804M AUM 0.18% 1-Year Est. Return

Rhenman & Partners Asset Management's Q3 2024 Portfolio in Review

As of Q3 2024, Rhenman & Partners Asset Management held 101 positions worth $1.23B, up 18% from $1.04B the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Rhenman & Partners Asset Management deployed $102M of net new capital in Q3 2024, opening 8 new positions and adding to 39 existing holdings. Its largest new stake was Novo Nordisk: 100,000 shares worth $11.9M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Industrials.

On the sell side, the largest reduction was Elevance Health, an estimated $18.9M trimmed.

  • Rhenman & Partners Asset Management's largest Q3 2024 buy was Novo Nordisk: 100,000 shares worth $11.9M.
  • Rhenman & Partners Asset Management added most to Inspire Medical Systems in Q3 2024, an estimated $18.2M increase.
  • Rhenman & Partners Asset Management's biggest Q3 2024 reduction was Elevance Health, cutting an estimated $18.9M.
  • Rhenman & Partners Asset Management fully exited Edwards Lifesciences in Q3 2024, selling an estimated $9.01M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 31% of its $1.23B portfolio in Q3 2024.
  • Rhenman & Partners Asset Management opened 8 new positions and closed 6 in Q3 2024.
  • Rhenman & Partners Asset Management's portfolio value rose 18% quarter-over-quarter to $1.23B.

Based on Rhenman & Partners Asset Management's 13F filing for Q3 2024, filed 13 Nov 2024.